

List of additional members of SANI

Luisa Brussino¹, Cecilia Calabrese², Gianna Camiciottoli³, Giovanna Elisiana Carpagnano⁴, Stefano Centanni⁵, Angelo Guido Corsico⁶, Maria Teresa Costantino⁷, Alice D'Adda⁸, Simona D'Alo⁹, Maria D'Amato¹⁰, Stefano Del Giacco¹¹, Fabiano Di Marco¹², Nicola Cosimo Facciolo¹³, Eustachio Nettis¹⁴, Eleonora Nucera^{15,16}, Giovanni Passalacqua¹⁷, Girolamo Pelaia¹⁸, Luisa Ricciardi¹⁹, Luca Richeldi²⁰, Erminia Ridolo²¹, Pierachille Santus²², Nicola Scichilone²³, Giulia Scioscia²⁴, Giuseppe Spadaro²⁵, Paolo Tarsia²⁶

¹ Dipartimento di Scienze Mediche, Università degli Studi di Torino; SCDU Immunologia e Allergologia, AO Ordine Mauriziano Umberto I, Torino, Italy

² Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy

³ UNIT ASMA GRAVE - Ambulatorio Asma Grave Pneumologia e Fisiopatologia Toraco-Polmonare, Azienda Ospedaliera Universitaria Careggi (FI), Florence, Italy

⁴ Department of Translational Biomedicine and Neuroscience "DiBraIn", University of Bari Aldo Moro, Bari, Italy

⁵ Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, University of Milan, Milan, Italy

⁶ Division of Respiratory Diseases, IRCCS Policlinico San Matteo, Foundation and Department of Internal Medicine and Therapeutics, University of Pavia, Italy

⁷ Allergy and Clinical Immunology Unit, Department of Medicine, "Carlo Poma" Hospital Mantova, Italy

⁸ Broncopneumologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

⁹ UOC Allergologia - PO Civitanova Marche - AREA VASTA 3, Civitanova Marche, Italy

¹⁰ Department of Respiratory Medicine, University "Federico II" of Naples, Italy

¹¹ Unit of Allergy and Clinical Immunology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy

¹² Pulmonary Medicine Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy

¹³ UOC di Pneumologia, Arcispedale S. Maria Nuova Azienda USL di Reggio Emilia, Italy

¹⁴ Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy

¹⁵ Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore Roma, Italy

¹⁶ UOSD Allergologia e Immunologia Clinica, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore Roma, Italy

¹⁷ Clinica di Malattie Respiratorie e Allergologia, Dip. Medicina Interna, Univ. degli Studi di Genova, IRCCS- AOU San Martino, Genova, Italy

¹⁸ U.O. Malattie dell'Apparato Respiratorio, A.O.U. Mater Domini, Catanzaro, Italy

¹⁹ Allergologia e Immunologia Clinica, AOU Policlinico G. Martino - Università di Messina, Messina, Italy

²⁰ Fondazione Policlinico Universitario A. Gemelli, IRCCS Catholic University of Rome, Italy

²¹ Department of Medicine and Surgery, University of Parma, Parma, Italy

²² Department of Clinical and Biomedical Sciences, University of Milan, Respiratory Diseases, Sacco University Hospital, ASST Fatebenefratelli-Sacco, Milan, Italy

²³ U.O.C. Pneumologia, Azienda Ospedaliera Universitaria Policlinico P. Giaccone di Palermo, Italy

²⁴ Malattie Apparato Respiratorio, Dipartimenti delle funzioni Mediche e Sanitarie, Azienda Ospedaliero Universitaria - Ospedali Riuniti, Foggia, Italy

²⁵ Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy

²⁶ Pneumology Unit, Grande Ospedale Metropolitano Niguarda, Milan, Italy

Table S1: Descriptive statistics with a summary output of a mixed model on FeNO and lung function parameters recorded at baseline and during the treatment with benralizumab (n=108 unless otherwise specified). Mean (SD) and n values or n (percentage) and beta regression coefficients with 95% CI are reported for each time point.

Parameter	Baseline	Month 6	Month 12	Month 24	Month 36	p-value
FeNO	61.95 (55.66) 0 n=55	28.74 (21.06) -29.69 (-40.63:-18.75) n=49	32.22 (20.23) -25.27 (-37.73:-12.8 n=35	41.25 (36.92) -20.2 (-32.82:-7.57) n=33	42.27 (32.31) -18.21 (-30.01:-6.41) n=40	0.0001
FCV predicted (%)	93.97 (20.73) 0 n=91	99.92 (20.58) 6.57 (2.99:10.14) n=80	102.26 (24.52) 9.29 (5.49:13.08) n=67	100.19 (19.42) 8.84 (4.98:12.71) n=64	101.59 (19.38) 8.34 (4.69:11.98) n=76	<0.0001
Post BD FEV₁ (L/min.)	2.27 (0.72) 0 61	2.55 (0.77) 0.21 (0.08:0.34) 42	2.80 (0.74) 0.25 (0.09:0.40)	2.65 (0.87) 0.14 (-0.01:0.28) 27	2.54 (0.96) 0.16 (0.02:0.30) 37	0.0397
Post BD FEV₁ predicted (%)	87.13 (21.72) 0 n=63	93.97 (23.48) 7.34 (1.51:13.17) n=42	99.11 (17.11) 9.72 (2.87:16.58) n=27	96.8 (20.46) 7.8 (1.43:14.17) n=35	92.97 (25.95) 6.42 (0.3:12.53) n=38	0.1703
Post-BD FCV predicted (%)	87.06 (36.79) 0 n=60	102.9 (23.35) 14.03 (3.28:24.79) n=40	107.93 (21.28) 16.26 (3.83:28.68) n=27	104.08 (31.68) 11.29 (-0.3:22.88) n=34	94.36 (40.22) 3.49 (-7.59:14.56) n=38	0.1703
FEV₁/FVC	54.11 (24.87) 0 n=91	58.95 (25.79) 5.84 (3.52:8.17) n=81	57.02 (27.91) 4.76 (2.28:7.24) n=67	63.83 (18.93) 5.04 (2.5:7.58) n=63	60.7 (24.58) 6.26 (3.87:8.66) n=75	<0.0001
Post BD FEV₁/FVC	62.82 (21.32) 0 n=60	71.82 (9.8) 2.86 (0.71:5.01) n=41	71.55 (9.69) 1.82 (-0.68:4.31) n=27	69.9 (8.16) 1.12 (-1.21:3.44) n=36	68.66 (14.24) 2.15 (-0.06: 4.36) n=40	0.2822

Table S2: Extent of OCS dose reduction during treatment with benralizumab in patients grouped according to OCS dose at baseline (≤5 mg/day or >5 mg/day)

Extent of OCS reduction, OCS dose at baseline ≤5 mg/day (n=26)	Month 6 (n=25)	Month 12 (n=21)	Month 24 (n=21)	Month 36 (n=21)
<i>Any reduction</i>	20 (80%)	20 (95.24%)	18 (85.71%)	19 (90.48%)
≥90 %	14 (56%)	18 (85.71%)	16 (76.19%)	18 (85.71%)
≥75 %	15 (60%)	19 (90.48%)	17 (80.95%)	18 (85.71%)
≥50 %	19 (76%)	20 (95.24%)	17 (80.95%)	19 (90.48%)
≥25 %	20 (80%)	20 (95.24%)	18 (85.71%)	19 (90.48%)
<i>No reduction</i>	5 (20%)	1 (4.76%)	3 (14.29%)	2 (9.52%)
<i>Elimination</i>	14 (56%)	18 (85.71%)	16 (76.19%)	18 (85.71%)
Extent of OCS reduction, OCS dose at baseline >5 mg/day (n=41)	Month 6 (n=39)	Month 12 (n=26)	Month 24 (n=22)	Month 36 (n=24)
<i>Any reduction</i>	32 (82.05%)	21 (80.77%)	21 (95.45%)	23 (95.83%)
≥90 %	25 (64.1%)	16 (61.54%)	18 (81.82%)	20 (83.33%)
≥75 %	27 (69.23%)	19 (73.08%)	20 (90.91%)	21 (87.5%)
≥50 %	31 (79.49%)	21 (80.77%)	21 (95.45%)	23 (95.83%)
≥25 %	31 (79.49%)	21 (80.77%)	21 (95.45%)	23 (95.83%)
<i>No reduction</i>	7 (17.95%)	5 (19.23%)	1 (4.55%)	1 (4.17%)
<i>Elimination</i>	25 (64.1%)	16 (61.54%)	17 (77.27%)	20 (83.33%)

Figure S1: Number and percentage of patients who achieved and did not achieve CR (either pCR or cCR) at 12, 24, and 36 months during the treatment with benralizumab (values calculated from baseline).

